EU's CHMP gives nod to Merck and Cardiome's Brinavess
This article was originally published in Scrip
Executive Summary
The EU's CHMP has supported the approval of Merck & Co/Cardiome Pharma's Brinavess (vernakalant HCl) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. The opinion covers its use for non-surgery patients with atrial fibrillation of seven days or less and for post-cardiac surgery patients with atrial fibrillation of three days or less duration.